Increasing prevalence and growing awareness of this disorder are driving the seasonal affective disorder market growth. Increasing number of physician visits related to seasonal affective disorder is increasing which is another growth factor for the market. Some other factors such as changing lifestyle and lack of exercise are also key drivers for the market growth. Availability and adoption of new treatments for this disorder are another important factor for the market growth. The seasonal affective disorder market is growing moderately and is expected to continue its growth during the forecast period.
Key Players in the Global Seasonal Affective Disorder Market
Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc. (US), Pfizer Inc. (US), and others
Segments
The seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.
On the basis of diagnosis, the seasonal affective disorder market is segmented into physical exam, lab tests, psychological evaluation, and others. Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others. Psychological evaluation includes intelligence tests, personality tests, attitude tests, achievement tests, aptitude tests, neuropsychological tests, vocational tests, direct observation tests, and others.
On the basis of treatments, the seasonal affective disorder market is segmented into light therapy (phototherapy), medications, psychotherapy, counselling, and others. Medications includes antidepressants, and others. Antidepressants is further sub-segmented into reuptake inhibitors (SSRIs), and others. Psychotherapy includes art therapy, attachment-based psychotherapy, behavioral therapy, body psychotherapy, Cognitive analytical therapy (CAT), existential psychotherapy, gestalt therapy, and others.
On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.
Regional Analysis of the Global Seasonal Affective Disorder Market
The Americas hold the largest share in the global Seasonal affective disorder market. North America dominates the market in this region. Approximately 5% of the US population is suffering from seasonal depression Some other factors such as changing lifestyle plays an important role in market growth. South America market is also growing significantly, especially growth is higher in countries such as Brazil due to increasing awareness about various mental disorders.
The number of patients affected by seasonal affective disorder is increasing in Europe. The prevalence rate is higher in UK and Ireland. Approximately 2% population of Northern Europe is suffering from severe depression which results into seasonal affective disorder. Other European countries such as Germany and France are holding major market share in this region.
The prevalence of seasonal affective disorder in Asia Pacific region is about 0.9% which is lower as compare to North America and Europe. However, people are getting more aware about this disorder which is driving the seasonal affective disorder market growth. Some other factors such as developing health facilities, availability of treatments and products, changing lifestyle etc. are playing an important role in the growth of this market.
Due to low prevalence rate, less awareness of this disorder, and limited access to the healthcare facilities, Middle East & Africa seasonal affective disorder market is growing slower than the global average. The Middle Eastern countries are dominating this market due to developed healthcare infrastructure and increasing expenditure on health.
Sources: The National Institute of Mental Health (NIMH), National Center for Biotechnology Information, U.S. National Library of Medicine, American Psychological Association, Directorate of Industries, annual report, white paper, company presentation
